RGNX
Price
$10.61
Change
-$0.25 (-2.30%)
Updated
Feb 4, 03:14 PM (EDT)
Capitalization
549.77M
27 days until earnings call
Intraday BUY SELL Signals
ZBIO
Price
$21.00
Change
+$1.28 (+6.49%)
Updated
Feb 4, 03:29 PM (EDT)
Capitalization
1.06B
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RGNX vs ZBIO

Header iconRGNX vs ZBIO Comparison
Open Charts RGNX vs ZBIOBanner chart's image
REGENXBIO
Price$10.61
Change-$0.25 (-2.30%)
Volume$200
Capitalization549.77M
Zenas Biopharma
Price$21.00
Change+$1.28 (+6.49%)
Volume$500
Capitalization1.06B
RGNX vs ZBIO Comparison Chart in %
RGNX
Daily Signal:
Gain/Loss:
ZBIO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
RGNX vs. ZBIO commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGNX is a Hold and ZBIO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (RGNX: $10.86 vs. ZBIO: $19.72)
Brand notoriety: RGNX and ZBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGNX: 82% vs. ZBIO: 79%
Market capitalization -- RGNX: $549.77M vs. ZBIO: $1.06B
RGNX [@Biotechnology] is valued at $549.77M. ZBIO’s [@Biotechnology] market capitalization is $1.06B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGNX’s FA Score shows that 1 FA rating(s) are green whileZBIO’s FA Score has 0 green FA rating(s).

  • RGNX’s FA Score: 1 green, 4 red.
  • ZBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, both RGNX and ZBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGNX’s TA Score shows that 5 TA indicator(s) are bullish while ZBIO’s TA Score has 5 bullish TA indicator(s).

  • RGNX’s TA Score: 5 bullish, 5 bearish.
  • ZBIO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ZBIO is a better buy in the short-term than RGNX.

Price Growth

RGNX (@Biotechnology) experienced а -19.02% price change this week, while ZBIO (@Biotechnology) price change was -1.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

RGNX is expected to report earnings on Mar 03, 2026.

ZBIO is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZBIO($1.06B) has a higher market cap than RGNX($550M). RGNX YTD gains are higher at: -24.583 vs. ZBIO (-45.690). RGNX has higher annual earnings (EBITDA): -120M vs. ZBIO (-195.62M). ZBIO has more cash in the bank: 291M vs. RGNX (274M). ZBIO has less debt than RGNX: ZBIO (798K) vs RGNX (76.5M). RGNX has higher revenues than ZBIO: RGNX (161M) vs ZBIO (15M).
RGNXZBIORGNX / ZBIO
Capitalization550M1.06B52%
EBITDA-120M-195.62M61%
Gain YTD-24.583-45.69054%
P/E RatioN/A1.44-
Revenue161M15M1,073%
Total Cash274M291M94%
Total Debt76.5M798K9,586%
FUNDAMENTALS RATINGS
RGNX vs ZBIO: Fundamental Ratings
RGNX
ZBIO
OUTLOOK RATING
1..100
5759
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6064
P/E GROWTH RATING
1..100
2292
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZBIO's Valuation (48) in the null industry is in the same range as RGNX (73) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to RGNX’s over the last 12 months.

ZBIO's Profit vs Risk Rating (100) in the null industry is in the same range as RGNX (100) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's SMR Rating (98) in the Biotechnology industry is in the same range as ZBIO (100) in the null industry. This means that RGNX’s stock grew similarly to ZBIO’s over the last 12 months.

RGNX's Price Growth Rating (60) in the Biotechnology industry is in the same range as ZBIO (64) in the null industry. This means that RGNX’s stock grew similarly to ZBIO’s over the last 12 months.

RGNX's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for ZBIO (92) in the null industry. This means that RGNX’s stock grew significantly faster than ZBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGNXZBIO
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 14 days ago
77%
Bullish Trend 8 days ago
90%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
69%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
RGNX
Daily Signal:
Gain/Loss:
ZBIO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSDQX18.390.36
+2.00%
Morgan Stanley Emerging Mkt ex China A
AFNIX25.120.08
+0.32%
Bahl & Gaynor Income Growth I
KTRIX9.42-0.01
-0.11%
DWS Global Income Builder Inst
ADGIX25.59-0.32
-1.24%
AB Core Opportunities I
LEGCX49.32-0.94
-1.87%
Columbia Cornerstone Growth C

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with BEAM. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+0.74%
BEAM - RGNX
57%
Loosely correlated
-0.11%
VYGR - RGNX
55%
Loosely correlated
-2.25%
BCYC - RGNX
54%
Loosely correlated
-7.55%
SYRE - RGNX
54%
Loosely correlated
+1.65%
XNCR - RGNX
54%
Loosely correlated
-0.99%
More

ZBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZBIO has been loosely correlated with RGNX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBIO jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZBIO
1D Price
Change %
ZBIO100%
+8.65%
RGNX - ZBIO
44%
Loosely correlated
+0.74%
PYXS - ZBIO
43%
Loosely correlated
-2.61%
SYRE - ZBIO
42%
Loosely correlated
+1.65%
XENE - ZBIO
42%
Loosely correlated
+1.62%
REPL - ZBIO
41%
Loosely correlated
+5.81%
More